New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2013
07:05 EDTNUVANuVasive operating margin poised to increase, says William Blair
After meeting with NuVasive's manement, William Blair believes that the company's operating margin will increase significantly in coming years. The firm thinks that the company can continue to gain market share and it recommends buying the stock at current levels.
News For NUVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
08:15 EDTNUVANuVasive price target raised to $48 from $44 at Summer Street
Subscribe for More Information
November 17, 2014
10:02 EDTNUVAOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: CyrusOne (CONE) upgraded to Buy from Hold at Stifel... MGIC Investment (MTG) upgraded to Conviction Buy from Buy at Goldman... NuVasive (NUVA) upgraded to Outperform from Market Perform at Wells Fargo... Phillips 66 (PSX) upgraded to Outperform from Neutral at Credit Suisse... Pinnacle Foods (PF) upgraded to Buy from Hold at Deutsche Bank... Rayonier (RYN) upgraded to Outperform from Sector Perform at RBC Capital.. Thoratec (THOR) upgraded to Outperform from Market Perform at Wells Fargo... Volcano (VOLC) upgraded to Outperform from Neutral at Credit Suisse... Progressive Waste (BIN) upgraded to Neutral from Underperform at Macquarie... Clean Harbors (CLH) upgraded to Outperform from Neutral at Wedbush... McGraw Hill Financial (MHFI) upgraded to Buy from Hold at Benchmark Co... Chesapeake (CHK) upgraded to Outperform from Market Perform at Bernstein... American Science & Engineering (ASEI) upgraded to Fair Value from Sell at CRT Capital... Sony (SNE) upgraded to Overweight from Equal Weight at Morgan Stanley.
05:39 EDTNUVANuVasive upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo upgraded NuVasive to Outperform after attending last week's North American Spine Society annual meeting. Wells believes the worldwide spine market continues to improve and that NuVasive is well positioned to capitalize on the momentum. The firm raised its price target range for shares to $50-$52 from $43-$44.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use